Fatty acid modified forms of glucocorticoids

• US 20040235811A1
• Filed: 10/08/2003
• Published: 11/25/2004
• Est. Priority Date: 10/08/2002
• Status: Abandoned Application

• Current Assignee: Sepracor Incorporated (Sumitomo Chemical Company Limited)
• Original Assignee: Sepracor Incorporated (Sumitomo Chemical Company Limited)
• Inventors: Jones, Steven, Currie, Mark G., Zepp, Charles M.
• Application Number:
  US10/681,614
• Publication Number:
  US 20040235811A1
• Time in Patent Office: Days
• US Class Current: 514/179
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: C07J 5/00 Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
• CPC Class Codes: C07J 5/0076 by an alkyl group
• CPC Class Codes: C07J 5/0092 by an OH group free esterified or etherified
• CPC Class Codes: C07J 71/0031 at positions 16, 17

Abstract

Compounds are disclosed of the formula

in which R³ is C₈ to C₂₄ hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly by inhalation, and for treating inflammation, particularly by local or topical administration.

Claims

1. A compound of Formula I:

2. A compound according to claim 1 of formula:

3. A compound according to claim 2 of formula:

4. A compound according to claim 2 of formula

5. A compound according to claim 2 of formula

6. A compound according to claim 1 of formula:

7. A compound according to claim 4 wherein R³ is the residue of phytanic acid:

8. A compound according to claim 4 wherein R³ is the residue of eicosapentaenoic acid

9. A compound according to claim 4 wherein R³ is the residue of docosapentaenoic acid:

10. A compound according to claim 4 wherein R³ is the residue of docosahexaenoic acid:

11. A pharmaceutical formulation for inhalation comprising a compound according to claim 1 and a pharmaceutically acceptable fluid for solution or suspension.

12. A pharmaceutical formulation according to claim 11 additionally comprising a propellant.

13. A method for treating bronchospasm comprising administering a compound of claim 1.

14. A method for inducing bronchodilation comprising administering a compound of claim 1.

15. A method for treating inflammatory conditions comprising administering a compound of claim 1.

16. A method according to claim 15 wherein said inflammatory condition is chronic obstructive pulmonary disease.

17. A method according to claim 15 wherein said inflammatory condition is asthma.

18. A method according to claim 15 wherein said inflammatory condition is rhinitis.

19. A method according to claim 15 wherein said compound is administered by inhalation.